Opko Health, Inc. · NASDAQ:OPK
Opko Health — Lazard Capital Markets 6th Annual Healthcare Conference 2009
27 slides from Opko Health's conference presentation, Nov 17, 2009
Slide 1: Lazard Capital Markets 6th Annual Healthcare Conference
Lazard Capital Markets 6th Annual Healthcare Conference November 17 - 18, 2009 New York, NY Jamie Freedman, MD, PhD Executive Vice President, R&D
Slide 2: Cautionary Statement
Cautionary Statement 2 This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "s
Slide 3: OPKO Health, Inc.
OPKO Health, Inc. A specialty healthcare company building a diverse portfolio of important medical products with significant commercial value 3
Slide 4: OPKO Summary
OPKO Summary Expanding portfolio of medical products through internal R&D and licensing/acquisitions Opportunistic acquisitions of mature, profit-generating pharmaceutical businesses Private investments into high potential biotechnology companies 4
Slide 5: Board of Directors
Board of Directors Phillip Frost, MD Chairman of the Board & CEO Jane Hsiao, PhD, MBA Vice-Chairman & CTO Steve Rubin, JD Director and Exec. VP Administration Richard Lerner, MD President, The Scripps Research Institute Pascal Goldschmidt, MD Dean, University of Miami School of Medicine Alice Yu, MD
Slide 6: Management Team
Management Team Phillip Frost, MD CEO & Chairman of the Board Jane Hsiao, PhD, MBA Vice-Chairman & Chief Technical Officer Steve Rubin, Exec. VP, Administration Rao Uppaluri, PhD, CFA Sr. VP & Chief Financial Officer Jamie Freedman, MD, PhD Exec. VP R&D 6
Slide 7: Financial History
Financial History Capital Investment Acuity Pharmaceuticals & Froptix (Pre-acquisition) $20.0 Million eXegenics (Public Company) $16.0 Million The Frost Group (December, 2007) $20.0 Million The Frost Group (September, 2008) $15.0 Million The Frost Group (April 2009) $20.0 Million Outside investors (
Slide 8: OPKO R&D Pipeline
OPKO R&D Pipeline 8 Products Mode of Action Indication Pre-Clinical Phase I Phase II Phase III Rolapitant NK1 Receptor Antagonist Emesis Doxovir Anti-Viral Viral Conjunctivitis Civamide Vanilloid Rec Antagonist Dry Eye Aquashunt Drainage Shunt Glaucoma SCH 900978 NK1 Receptor Antagonist Emesis siRNA
Slide 9: Nausea & Vomiting: A Steady Growth Market
Nausea & Vomiting A Steady Growth Market Major markets are N&V associated with chemotherapy and surgery >2 million chemo patients/year in US, EU, & Japan 23 million surgery patients/year in US & EU Mainstay of prevention are 5-HT3 antagonists and NK-1 antagonist (Emend(r)) 5-HT3 and NK-1 complementa
Slide 10: Rolapitant: Potential Best-in-Class NK-1
Rolapitant Potential Best-in-Class NK-1 Rolapitant acquired from Schering-Plough (Nov 2009) related to merger with Merck Phase 2 completed for chemotherapy and post-operative N&V (CINV/PONV) Oral and IV formulation in development Patent exclusivity for next 15+ years 10
Slide 11: Phase 2 Positive for PONV
Phase 2 Positive for PONV Significant reduction in emesis acute (24 hr) and delayed (120 hrs) 0.9 1 N=619 * * * * 58% 70% 73% 80% 87% 78% 52% 57% 76% 73% 62% 0.5 0.6 0.7 0.8 onse (%) * N 47% 0.1 0.2 0.3 0.4 Respo 0 PLA R 5 R 20 R 70 R 200 OND No Emesis 0-24 No Emesis 0-120 11 *Statistically signific
Slide 12: Rolapitant Differentiation and Plans
Rolapitant Differentiation and Plans Key properties that make rolapitant profile better than competition ("best-in-class") No clinically significant drug-drug interactions Single dose regimen offering durable protection (5 days post dose) First to document sustained benefit of 5 day protection in PO
Slide 13: Influenza
Influenza 200,000 hospitalizations and 46,000 deaths in U.S. each year Economic costs in U.S. ~$80 billion a year Annual "flu shot" against common strains Flu vaccine grown in chicken eggs Limitations: New vaccine each year Only partially protective Manufacturing capacity limited 13
Slide 14: Universal Flu Vaccine Preclinical Development
Universal Flu Vaccine Preclinical Development Universal flu vaccine licensed from Academia Sinica July 2009 Vaccine based on modified hemagglutinin Broad protection against variants High potency Preclinical development initiated Large-scale manufacturing process being determined 14
Slide 15: HA-Specific Antibody Response
HA-Specific Antibody Response A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses Ming-Wei Chen*+, Ting-Jen Rachel Cheng*, Yaoxing Huang+, Jia-Tsrong Jan*, Shiou-Hwa Ma*, ALice L. Yu*, Chi-Huey Wong*, and David D. Ho* 10000 1000 100 50 0 5 10 15 20
Slide 16: Molecular Diagnostics Overview
Molecular Diagnostics Overview Global molecular diagnostic market projected to reach ~$4B by 2010 Largest growth segments Early detection Companion diagnostics 16
Slide 17: Molecular Diagnostics: Small Molecule Microarray
Molecular Diagnostics Small Molecule Microarray Molecular microarray technology acquired June 2009 "Peptoids" as first example of small molecule array to detect disease- associated antibodies Broad application for diagnosing diseases by a simple blood test Neurological disorders (Alzheimers Disease)
Slide 18: Small Molecule Microarray Peptoid Methodology
Small Molecule Microarray Peptoid Methodology 18 HEALTHY DISEASE
Slide 19: Small Molecule Microarray Diagnosis of Alzheimers Disease
Small Molecule Microarray Diagnosis of Alzheimers Disease AD most common form of dementia Diagnosis relies on cognition tests and expensive imaging Molecular test would be useful in drug development 19 NC=Normal Control AD=Alzheimers Disease PD=Parkinson's Disease
Slide 20: Multiple Peptoid Applications
Multiple Peptoid Applications 20 Application Example Diagnostic Detection of disease and subpopulations Tissue-specific imaging agents Biomarkers to follow disease and response to therapy Therapeutic Identification of therapeutic targets Modulation of therapeutic targets (agonist or antagonist) Vacc
Slide 21: Wide range of ultrasound products
Wide range of ultrasound products A-Scan, B-Scan, 3D-Scan, UBM Distributed in 45 countries Ultrasound market ~$60M a year OPKO Instruments Ultrasound 21
Slide 22: OCT and SLO from single source
OCT and SLO from single source Precise pixel-to-pixel correlation of coronal OCT slice to SLO surface image Ultra-high resolution imaging of eye Diagnosis of retinal and other eye diseases 22 OPKO Instruments Integrated OCT and SLO OCT SLO OCT=Ocular coherence tomography SLO=Scanning laser ophthalmo
Slide 23: OPKO Instruments Microperimetry Add-On to OCT-SLO
OPKO Instruments Microperimetry Add-On to OCT-SLO Tests retinal function at level of photoreceptors in macula Functional-anatomical correlation Track visual function response to treatment Functional Sensitivity Map ~$250M annual market potential
Slide 24: Pharma Genexx Overview
Pharma Genexx Overview OPKO acquired Pharma Genexx (Chile) in Oct 2009 Rapidly growing sales and profits in Latin America Commercializing >90 products in multiple therapeutic areas 24
Slide 25: Pharma Genexx Total Sales
Pharma Genexx Total Sales US$ in millions 0 2 4 6 8 10 12 14 16 18 2007 2008 2009 Forecast US$ in millions 25
Slide 26: Minority Interest
Minority Interest Platform for human monoclonal antibodies 26 Protein structure-based anti-viral therapeutics Broad spectrum CoCrystal Discovery Inc.
Slide 27: OPKO Summary
OPKO Summary Rapid expansion of drug development portfolio, including late stage compounds Profitable pharmaceutical companies acquired Minority interest in high potential biotechnology companies 27
OPKO Health — Lazard Capital Markets 6th Annual Healthcare Conference 2009 on 6ix